Luscient Diagnostics

Lucent Diagnostics is a commercial diagnostics brand operated by Quanterix that focuses on blood-based biomarker testing for Alzheimer's disease and related cognitive decline. The brand markets laboratory-developed tests including LucentAD p-Tau 217 and LucentAD Complete, which use Quanterix's ultra-sensitive Simoa technology to assess amyloid pathology and support earlier clinical evaluation of patients with memory complaints. Its offering is provider-facing and appears to run through Quanterix's CLIA laboratory rather than as a standalone independent biotech company. Lucent Diagnostics has also expanded access through partnerships such as Life Line Screening to bring testing into community settings across the United States.